Sutro Biopharma Inc (STRO) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Sutro Biopharma Inc   (NASDAQ: STRO)


Sutro Biopharma Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Sutro Biopharma Inc's ROI in the second quarter of 2026?
Sutro Biopharma Inc recorded a cumulative net loss of $-181 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -131.56%.

Within the Healthcare sector 384 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3174 to 3611.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -42.33 % -46.96 % -51.31 % -44.25 % -32.84 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 142 171 99 138 188
Return On Investment (TTM) -131.56 % -103.13 % -124.7 % -112.67 % -87.66 %
STRO's Overall Ranking # 3611 # 3174 # 3404 # 2775 # 3347
Seq. Investment Change TTM -7.81 % -2.81 % -20.35 % -19.19 % -15.22 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -181 -154 -191 -217 -209

STRO Company Profile >> Back to STRO Roi Comparisons >> See Annual STRO Return On Investment



Return On Investment STRO's Ranking
Within: No.
Industry # 58
Sector # 385
Overall # 3611

Return On Investment Statistics
High Average Low
6.61 %
-34.45 %
-55.92 %
(Sep 30 2020)   (Sep 30 2025)



  News about Sutro Biopharma Inc Return on Investment ROI

Promising Results for Luvelta in Combating Late-Stage Ovarian Cancer Amidst Financial Turbulence for Sutro Biopharma

September 14, 2024

Sutro Biopharma, a biopharmaceutical company renowned for its innovative drug discovery and development, recently shared updated data from its Phase 1b study of Luvelta (luveltamab tazevibulin) in combination with the well-established anti-angiogenic therapy, Bevacizumab. This combination was presented at the European Society for Medical Oncology (ESMO) 2024 meeting and has garnered attention due to its significant impact on patients battling late-stage ovarian cancer.The study revealed that administering Luvelta at a dosage of 4.3 mg/kg alongside Bevacizumab administered at a standard dose of 15 mg/kg every three weeks yielded a remarkable response rate of 56%. This promising statistic suggests that over half of the treated patients experienced measurable tumor reduction, indicating not only the efficacy of this therapeutic combination but also the potential for Luvelta to play a pivotal role in late-stage ovarian cancer treatment. Consequently, this dosimetric regimens has been designated as the recommended Phase 2 dose (RP2D), laying the groundwork for future advancements in the clinical development of this promising therapeutic strategy.





Financial Statements
Sutro Biopharma Inc's II. Quarter Investments $ 142 Millions STRO's Balance sheet
Sutro Biopharma Inc's II. Quarter Income $ -39 Millions Quarterly STRO's Income Statement
STRO's Income by Division See STRO's Income by Division


STRO Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 99 255 377 340 300
Y / Y Investment Growth -61.34 % -32.28 % 10.75 % 13.59 % -17.79 %
Net Income in Millions -191 -227 -107 -119 -106
Y / Y Net Income Growth - - - - -
Annual Return On Investment -193.61 % -89.09 % -28.33 % -35.02 % -35.22 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
STRO's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for STRO's Competitors
Subscribers only: Roi for Sutro Biopharma Inc's Suppliers
Subscribers only: Return On Investment for STRO's Customers

Other Ratios
STRO's Roa STRO's Inventory Turnover Ratio STRO's Growth Rates STRO's Dividend Statistics
STRO's Profitability Ratios STRO's Asset Turnover Ratio STRO's Dividend Growth
STRO's Roe STRO's Valuation Ratios STRO's Financial Strength Ratios STRO's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-03T12:17:35+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.